http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
ZimVie Announces Completion of its Acquisition by ARCHIMED
-
Chicago Thanksgiving Parade Returns for Its 91st Year -- A Dazzling Celebration of Culture, Music & Community
-
Generation Essentials Group reports 160% revenue increase in first half
-
Merck KEYTRUDA shows long-term survival benefits in lung cancer patients
-
The Generation Essentials Group Reports on Half Year Performance with a ~160% Increase in Revenue
-
KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
-
Create a Snap for Change to improve road safety in your community
-
SGBX subsidiary Olenox plans drilling program starting Q4 2025
-
Cogent Biosciences receives FDA breakthrough therapy designation
-
Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
-
SGBX Subsidiary Olenox Energy Announces an Aggressive Drilling Agenda Slated to Begin Q4 2025 and Expand Throughout 2026
-
Water Tower Research Spotlights Ainos-NEXCOM Partnership as Catalyst for High-Growth Edge AI Expansion
-
Clene to Present at the Emerging Growth Conference
-
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
-
HTX Opens Trading for 4
-
AbbVie's RINVOQ outperforms HUMIRA in rheumatoid arthritis study
-
RedChip Companies Announces Sponsorship of the LD Micro Main Event XIX
-
Brainomix e-Lung Enables Earlier Detection of Progressive Pulmonary Fibrosis, New Study Shows
-
Early Registration Now Open for 4th Annual 5K at the Runway at Ontario International Airport
-
Signal Advance (OTC:SIGL) Achieves Major Encryption Milestone with Analog Guard
-
RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
-
UNLOCKD Inc. (OTCID: BFCH) - From Reset to Execution: Building the Public Platform for High-Growth Consumer Brands
-
Radiopharm Theranostics raises A$35 million in institutional placement, launches share buyback
-
Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan
-
Predictmedix AI Announces Non-Brokered Private Placement
-
Fortrea launches tender offer for up to $75.7 million of debt securities
-
Surge Battery Metals Advances 2025 Drill Program; Leverages U.S. Critical Minerals Policy
-
Westbridge Renewable Energy to Present at the Planet MicroCap Showcase in Toronto
-
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
-
Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt
-
BD launches AI-enabled platform for healthcare device connectivity
-
Imperfect but Unstoppable: Italian Wine Podcast Smashes 2500 Episodes to Become the World's Most Prolific Wine Podcast
-
BD Launches New AI-enabled Solutions to Drive Connectivity Across Healthcare Settings
-
Merck begins construction of $3 billion manufacturing facility in Virginia
-
Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
-
CoinEx Reinforces Transparency with Updated Proof of Reserve – October 2025
-
CoinLander Launches RWA Platform, Unlocking Stable Returns from Tokenized Real Estate Mortgages
-
Exelixis reports survival benefit for zanzalintinib combo in colorectal cancer
-
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
-
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO
-
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
-
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
-
Daiichi Sankyo and Merck's ovarian cancer drug shows 50.5% response rate
-
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-O
-
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
-
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
-
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
-
Crypto News (Live): From $0.0075 to $0.50? Blazpay’s AI Presale Heats Up as Solana and BNB Investors Seek New Gains
-
Darkness to Light Expands National Scholarship Program Empowering Child Protection Leaders
-
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-
